In chronic obstructive pulmonary disease (COPD) patients tiotropium bromide has been shown to improve forced expiratory volume in one second (FEV 1 ) and inspiratory capacity (IC). We investigated whether the mechanism leading to these improvements is related to small airways ventilation heterogeneity, assessed by multiple breath washout tests. Forty stable tiotropium-free COPD patients (FEV 1 : 27%-78% predicted) were studied before and 90 min after administration of tiotropium bromide on visit 0 , and following 3 and 6 weeks of tiotropium bromide treatment (visit 3wks , visit 6wks ). After study completion, COPD patients were classifi ed into two subgroups according to degree of hyperinfl ation at visit 0 (Hyp-, Hyp+). The Hyp+ group showed signifi cant increases in trough (ie, pre-dose) FEV 1 and IC after 3 and 6 weeks of tiotropium bromide, and the 90 min tiotropium bromide responses of FEV 1 and IC were signifi cant at visit 0 (p ≤ 0.001 for both) but not during subsequent visits. The Hyp-group showed signifi cant FEV 1 increases 90 min after tiotropium bromide on all three visits (all p Ͻ 0.005) but no sustained increase in trough values. In both COPD subgroups, the grossly abnormal ventilation heterogeneity barely showed any signifi cant improvements with tiotropium bromide in the conductive airways (without changes in trough value) and no changes at all in the acinar airways. We conclude that the sustained improvements in trough IC and FEV 1 with tiotropium bromide predominantly observed in COPD patients with considerable hyperinfl ation, are unrelated to small airways ventilation heterogeneity.
Introduction
Several clinical trials have investigated the effect of the long-acting anticholinergic bronchodilator, tiotropium bromide (Barnes et al 1995) , on lung function and dyspnea at rest (van Noord et al 2000; Vincken et al 2002; Casaburi et al 2002; Celli et al 2003; Brusasco et al 2003; Verkindre et al 2006) and during exercise (O'Donnell et al 2004; Casaburi et al 2005; Maltais et al 2005) , and assessed its infl uence on quality of life (Vincken et al 2002; Casaburi et al 2002; Brusasco et al 2003; Casaburi et al 2005; Verkindre et al 2006) or on the occurrence of exacerbations (Vincken et al 2002; Niewoehner et al 2005; Dusser et al 2006) in chronic obstructive pulmonary disease (COPD). Most of these studies indicated signifi cant and sustained improvements of the primary outcome parameters, and consistently reported improvements in forced expiratory volume in one second (FEV 1 ) and/or inspiratory capacity (IC) after different tiotropium bromide treatment periods up to one year. Given that tiotropium bromide is thought to act through its selective and prolonged binding to M 3 receptors (Gross 2004) , which are predominantly located in the large and medium-sized airways (Barnes 2004) , it could a priori be expected that the improvement in airway function would be mainly located in these larger conductive airways. While the observed FEV 1 improvements could be brought in agreement with this proposition, the IC improvements have prompted several authors to hint at the implication of small airways in this anticholinergic bronchodilation process (van Noord et al 2000; Verkindre et al 2006) .
We have recently shown that COPD patients are characterized by a combination of both large and small conductive airways ventilation heterogeneity, as opposed to smokers with similar smoking history but without COPD in whom only small airways are affected (Verbanck et al 2004) . This was measured with a model-based analysis of the multiple breath washout test which delivers independent phase III slope-derived indices of ventilation heterogeneity originating in the conductive and acinar lung zone (Scond and Sacin, respectively) (Verbanck et al 1997 (Verbanck et al , 1998 . In an earlier study, COPD patients have shown no signifi cant response of Scond or Sacin to 400 μg of salbutamol with a small spacer inhalation aid (Verbanck et al 1999) . In the present study, we use Scond and Sacin measurements to test the hypothesis that the small airways situated in the conductive and/or proximal acinar lung zones could participate to some degree in the tiotropium bromide response and thus affect inspiratory capacity, which is linked to dyspnea and exercise limitation in COPD patients (O'Donnell et al 2004) . In particular, this mechanistic study aims to investigate whether the reported benefi cial effects on pre-dose (trough) and peak values of FEV 1 and IC are paralleled by improvements in small airways heterogeneity. In order to assess whether any potential improvement in small airways ventilation heterogeneity was specifi cally linked to improvement in hyperinfl ation, we deliberately included COPD patients with varying degrees of hyperinfl ation at baseline (which is also representative of a real-life clinical situation).
Material and methods

Patients and procedures
The study protocol was approved by the local ethics committee. Forty patients with a clinical diagnosis of COPD for at least 2 years were recruited if they fulfi lled the following inclusion criteria: aged over 40 years, smoking history of at least 15 packyears, FEV 1 /forced vital capacity (FVC) Ͻ 70% and post bronchodilator FEV 1 Ͻ 80%pred. Patients with a history of concomitant asthma or atopy or patients requiring supplemental oxygen therapy were excluded. None of the patients had suffered any exacerbation in the six month period prior to the study, nor any recent upper respiratory tract infection. The COPD patients already on tiotropium bromide treatment were asked to discontinue tiotropium for at least 4 weeks before the screening visit. A written informed consent was obtained from all participating patients. Patients had been requested not to take any short-or long-acting bronchodilator medication for at least 8 h and 24 h, respectively, before each visit. There was 1 screening visit and 3 visits further referred to as study visits, ie, a baseline visit (visit 0 ) and two visits after respectively 3 and 6 weeks (visit 3wks and visit 6wks ) of tiotropium bromide therapy (18 μg dry powder inhaled via the HandiHaler R device once daily in the morning). On visit 3wks and visit 6wks , the last tiotropium bromide intake was on the morning preceding the study day.
On the screening visit, patients underwent lung function and ventilation distribution testing according to standardized procedures. Lung function included spirometry and plethysmographic measurement of specifi c airway conductance (sGaw) and IC (IC pl ). Given the potential problems with plethysmographic volume determination in the case of obstructed patients (Rodenstein and Stanescu 1982) , we also used the preferred method of IC computation (ie, the difference between open circuit functional residual and total lung capacity volume levels). For the computation and interpretation of ventilation heterogeneity indices Scond and Sacin, we refer to a previous description (Verbanck et al 1997) , which is briefl y summarized in the Appendix. The screening visit served to characterize patients in terms of lung function and ventilation heterogeneity, and to assess their room for reversibility by the combination of a short-acting anticholinergic and a fast-acting β 2 -agonist drug. Sixty minutes after inhalation of 80 μg of ipratropium bromide, an intermediate spirometry was performed, and additional bronchodilation was elicited by inhaling 400 μg of salbutamol. After another 30 min (ie, cumulative postbronchodilator time: 90 min),lung function and ventilation distribution testing was repeated.
On the baseline study visit (visit 0 ), patients fi rst underwent lung function and ventilation distribution testing, and were then instructed to inhale 18 μg of tiotropium bromide dry powder via the HandiHaler ® device for the fi rst time. After 60 min, intermediate spirometry was performed, and after 90 min, the study visit was concluded with lung function and ventilation distribution testing. The next two study visits (visit 3wks and visit 6wks ), after respectively 3 and 6 weeks of daily tiotropium bromide treatment, involved exactly the same procedure as that on visit 0 . Given that for these two study visits, the last tiotropium bromide intake had been on the morning preceding the study day, the 90 min effect of tiotropium bromide could be assessed on trough values of lung function and ventilation heterogeneity in the laboratory.
On each visit, patients rated their dyspnea on a visual analogue scale (VAS) and by means of the Medical Research Council (MRC) scale (ranging 1-5). Finally, patients also filled out a symptom score sheet for wheezing, shortness of breath, cough, and chest tightness ranging "not present","mild","moderate","severe" (scored 0-3 and summed to a total symptom score ranging 0-12).
Statistical analysis
Two-way repeated measures analysis of variance (ANOVA) (Statistica5.5, StatSoft, Tulsa, OK) was used to detect any differences between the 3 study visits prior to and 90 min after tiotropium bromide administration (2 factors: inter-visit and intra-visit tiotropium bromide effect). Oneway repeated measures ANOVA was used to detect any inter-visit differences on the symptom scores. Bonferroni adjustment was used to test for post-hoc differences. Spearman rank correlations were performed between changes in symptom or dyspnea scores and changes in lung function indices.
Results
The 40 patients (36M/4F) participating in this study were stable COPD patients on maintenance treatment mostly involving inhaled steroids (37/40) in combination with long-acting β 2 -agonists (37/40). All patients were also on a combination of short-acting β 2 -agonists and ipratropium bromide, but at study entry, ipratropium bromide was discontinued. Eight out of 40 patients were current smokers. Figure 1 shows a histogram of the residual volume over total lung capacity ratio (RV/TLC) measured at the screening visit before bronchodilator administration, in the patient group under study (n = 40). The median RV/TLC being 54.8%, the group was split into a subgroup with a high degree of hyperinfl ation if RV/TLC Ն 55% (Hyp + ; n = 20) and a subgroup with a low degree of hyperinfl ation if RV/TLC Ͻ 55% (Hyp -; n = 20). Table 1 shows lung function, ventilation heterogeneity and symptom scores prior to tiotropium bromide administration on the study visits visit 0 , visit 3wks and visit 6wks . For each parameter in Table 1 , change from baseline (Δ) was computed as the difference between the value of visit 6wks and that of baseline visit 0 in order to test for correlations of change. In the Hyp -group, none of the correlations between changes in symptom or dyspnea scores and changes in lung function parameters were signifi cant (p Ͼ 0.1 for all). In the Hyp + group, changes in total symptom or MRC score did not correlate with any lung function or ventilation heterogeneity changes Table 1 showing any signifi cant interor intra-visit change in this subgroup. Panels B in Figures 3-6 display the corresponding data for the Hyp -group. In the Hyp + group, FEV 1 ( Figure 3A ) and IC ( Figure  4A ) signifi cantly increased 90 min after the fi rst 18 μg tiotropium bromide dose on visit 0 (p Յ 0.001 for both), while no such intra-visit increases occurred during visit 3wks and visit 6wks (p Ͼ 0.1 for both). Intra-visit changes in sGaw ( Figure 5A ) showed a similarity with FEV 1 and IC behavior, in that sGaw also increased signifi cantly during the baseline visit 0 (p Ͻ 0.001) but not during visit 3wks or visit 6wks (p Ͼ 0.1). While Figure5A suggests an increase in trough sGaw value, this was not signifi cant (p > 0.05 for both), yet, when excluding the abovementioned outlier ( Figure 2B ; open circle), trough sGaw did increase signifi cantly from 0. Figure 6A indicates tendencies for intra-visit Scond decreases (ie, improvements) of the same order as that observed on the screening visit, averaging an 11% decrease over the three study visits, the Scond decrease only reached statistical signifi cance on the last visit (p = 0.02). The complementary indicators of small airway function, end-expiratory fl ow after 75% of forced expired vital capacity (FEF 75 ) and Sacin, did not present any inter-or intra-visit effect in this subgroup (p > 0.1 for all). 
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Anticholinergic therapy in COPD
Two supplementary analyses were performed to verify whether the observed patterns, that appear to be specifi cally linked to the presence of hyperinfl ation, were not a consequence of (a) the expected difference in disease severity (in terms of FEV 1 ) . On the fi rst study visit, patients were tiotropium-free, while the other two study visits followed 3 and 6 weeks of tiotropium once-daily treatment with the last tiotropium intake on the day prior to the study visit; asterisks indicate any signifi cant change 90 min after tiotropium (2-way ANOVA with Bonferroni; p < 0.05). . On the fi rst study visit, patients were tiotropium-free, while the other two study visits followed 3 and 6 weeks of tiotropium oncedaily treatment with the last tiotropium intake on the day prior to the study visit; asterisks indicate any signifi cant change 90 min after tiotropium (2-way ANOVA with Bonferroni; p < 0.05); the dotted line represents the predicted IC value for this subgroup. B: IC obtained from the Hyp − group.
COPD groups. The discrepancy between the behavior of IC and ventilation heterogeneity in the hyperinflated COPD subgroup, makes it unlikely that small airways are implicated in the sustained improvements of IC observed by us and others. The modest intra-visit Scond decreases (reaching p = 0.05 significance on only one occasion) imply that tiotropium bromide action is either affecting heterogeneity of the larger conductive airways (thus not affecting small airways heterogeneity) or acting in a very homogeneous way at the level of the small conductive airways (thus not affecting small airways heterogeneity). However, the absence of any FEF 75 change with tiotropium bromide makes the latter possibility highly unlikely. Rather, the difference in patterns of sGaw improvements between Hyp -and Hyp + groups, similar to that observed for IC and FEV 1 , suggests that larger airways or large lung units subtended by these large airways play a major role in the short-and long-term effect of tiotropium bromide. The sustained improvement of FEV 1 and IC after 3 and 6weeks of tiotropium bromide treatment only occurred in COPD patients with considerable hyperinfl ation (Hyp + ).
Nevertheless, while the Hyp-patients showed no longterm FEV 1 or IC effects, their short-term FEV 1 increases (90 min after tiotropium bromide) on each study visit were of the same magnitude as those obtained at baseline visit in Hyp + patients. No such similarity between short-term improvements across both COPD subgroups was observed for IC. This indicates that the mechanism and site of bronchodilatation of tiotropium bromide (refl ected in FEV 1 ) are essentially the same in both COPD groups, but that when considerable hyperinfl ation is present, a continued bronchodilating action has the additional benefi t of relieving hyperinfl ation (refl ected in an IC improvement). The similar degree of bronchodilation in both groups suggests that any potential effect of the baseline state of hyperinfl ation on pulmonary distribution of the tiotropium bromide aerosol was negligible. In addition, the observed large airway effect suggests that either tiotropium bromide deposition was effectively confi ned to the large conductive airways, or that this was the only effective site of tiotropium bromide action on M 3 receptors. The trough IC and FEV 1 values in the Hyp + group after 3 and 6 weeks of tiotropium bromide treatment were indistinguishable from the respective peak values seen at the baseline visit 90 min after tiotropium bromide. This . On the fi rst study visit, patients were tiotropium-free, while the other two study visits followed 3 and 6 weeks of tiotropium once-daily treatment with the last tiotropium intake on the day prior to the study visit; asterisks indicate any signifi cant change 90 min after tiotropium (2-way ANOVA with Bonferroni; p < 0.05). B: S cond obtained from the Hyp − group.
bromide as an add-on study medication, as opposed to most previous studies where long-acting β 2 agonists were not permitted. This may account for some quantitative differences of tiotropium bromide effects with respect to previous studies (here, typical changes in FEV 1 trough value are 10% baseline in Hyp + patients). Secondly, in those previous studies where hyperinflation was not part of the inclusion criteria, the COPD groups under study may have been a mixture of patients with a range of hyperinflation. One would then expect a pattern which is intermediate to that seen in our Hyp + and Hyp -groups, corresponding to a partial increase in trough FEV 1 and IC values between baseline and treatment visits, and an additional intra-visit increase from trough to peak FEV 1 or IC value. Thirdly, the method of IC measurement varied across previous tiotropium bromide studies, using the difference between spirometric volume levels corresponding to FRC and TLC (corresponding to IC here) or that derived from plethysmographic FRC and TLC measurements (corresponding to IC pl here). The pitfalls inherent to plethysmographic volume determination in COPD have been documented before (Rodenstein and Stanescu 1982) and the difference between IC and IC pl behavior across Tables 1 to 3 emphasizes the interpretation problems with plethysmographically determined lung volumes.
In conclusion, we have observed a pattern of improved airfl ow (FEV 1 ) and inspiratory lung capacity (IC) with tiotropium bromide in COPD patients, which was linked to their degree of hyperinfl ation at baseline. In patients with a low degree of hyperinfl ation, FEV 1 and IC showed consistent increases, but no sustained changes in trough FEV 1 or IC. By contrast, in COPD patients with considerable hyperinfl ation at baseline, 3 weeks of tiotropium bromide treatment elicited improvements in trough IC and FEV 1 , close to the maximum obtainable value. The concomitant sGaw changes suggest that the main therapeutic effect is elicited in the large conductive airways. Ventilation heterogeneity of the acinar airways was unaffected by tiotropium bromide, and the modest improvements in Table 2 Characteristics of FEV 1 matched subgroups with RV/TLC Ն 55% (Hyp + ) OR Ͻ 55% (Hyp -) and the effect of tiotropium Ventilation distribution testing
The ventilation distribution test, ie, the multiple breath washout (MBW), was carried out using a computer-controlled bag-in-box breathing assembly. Tidal volume was targeted at 1 L and after a period of air breathing with stable end-expiratory lung volume at functional residual capacity, inspired air was switched to the test gas mixture. The test gas mixture consisted of pure O 2 , and 1 L tidal breathing continued for 20-25 breaths depending on the subject's lung volume (dilution); exhaled N 2 concentration tracings were analyzed. From the MBW N 2 tracings, indices Scond and Sacin were derived to represent the conductive and acinar components of ventilation heterogeneity, respectively, using an analysis that can be summarized as follows. During each expiration, the N 2 phase III slope is computed and normalized by the mean expired N 2 concentration. This leads to a normalized N 2 slope (Sn) which increases as a function of breath number or lung turnover ( Figure A1 ); lung turnover is determined as the cumulative expired volume divided by ventilated functional residual capacity, which is computed from a mass balance of the MBW test. On theoretical grounds it can be shown that: (a) the rate of rise of the Sn curve is due to the convective fl ow asynchrony between lung units larger than acini, thus, due to heterogeneity originating in the conductive airways; (b) the offset of the Sn curve is mainly determined by diffusion-convection dependent heterogeneity generated in the acinar airways. Hence, Scond is simply computed as the rate of Sn increase as a function of lung turnover, between 1.5 and 6 lung turnovers. Then, Sacin is computed as the Sn value of the fi rst MBW expiration minus a correction term to discard any conductive lung zone contribution; this correction term equals the lung turnover corresponding to the fi rst breath, multiplied by Scond. Illustrated in Figure , respectively. The theory of MBW phase III slope analysis leading to indices Scond and Sacin implies that ventilation heterogeneity can be attributed to different lung depths, ie, to the conductive and acinar lung zone, respectively, and that Scond and Sacin are intrinsically independent and are not comparable between each other (despite having the same dimension, L -1 ). Finally, since Scond and Sacin are derived from phase III slopes, their value increases when ventilation heterogeneity increases. In particular, Sacin will increase if ventilation heterogeneity is increased in the acinar lung zone, due to an alteration of the intra-acinar asymmetry (eg, unequal narrowing of affected respiratory bronchioles). On the other hand, Scond will increase when heterogeneous narrowing of conductive airways induces an alteration in the specifi c ventilation and/or fl ow asynchrony between the lung units subtended by these airways proximal to the terminal bronchioles.
An increase in Scond refl ects uneven narrowing of either the large or the small conductive airways, or both. A disproportionate Scond increase with respect to the decrease of large airway parameters such as FEV 1 or specifi c airway conductance can be used to identify the small airways component of conductive lung zone heterogeneity. An increase in Sacin represents a change in intra-acinar structural asymmetry, due to uneven narrowing of respiratory bronchioles or due to partial destruction of parenchyma, or both. Again, a disproportionate Sacin increase with respect to a decrease of diffusion capacity enables the identifi cation of the nonemphysematous component of acinar lung zone heterogeneity. 
